Related Experiment Video
Updated: Oct 14, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Pathophysiology and Pharmacological Management of Chronic Liver Injury: Current Challenges and Future Directions
Naziya Parveen1, Mayank Kumar1, Monojit Das1
1Narayan Institute of Pharmacy, Gopal Narayan Singh University, Jamuhar, Sasaram, Rohtas, 821305, Bihar, India.
Introduction:
Chronic liver injury results from persistent hepatic injuries such as metabolic disorders, alcohol consumption, viral infections, drug toxicity, autoimmune conditions, and genetic factors. It is a major global health concern due to its progression to fibrosis, cirrhosis, and hepatocellular carcinoma. This review aims to summarize key pathophysiological mechanisms and evaluate current and emerging pharmacological strategies.
Methods:
A narrative review of preclinical and clinical studies was conducted, focusing on inflammation, oxidative stress, immune dysfunction, fibrogenesis, and therapeutic approaches, including conventional drugs, antifibrotics, metabolic modulators, and advanced drug delivery systems. A total of 352 records were identified, of which 158 studies were included in the review.
Results:
Chronic liver injury is characterized by persistent inflammation, oxidative stress, hepatocyte death, impaired regeneration, and activation of hepatic stellate cells, leading to extracellular matrix accumulation and fibrosis. Current therapies are largely etiology-based and slow disease progression but rarely reverse fibrosis. Emerging therapies targeting nuclear receptors, metabolic pathways, gene-based interventions, microbiome modulation, and nanocarrier-based systems show promising potential.
Discussion:
These findings indicate that chronic liver injury is a complex, multifactorial process involving interconnected molecular pathways, limiting the effectiveness of single-target therapies. The gap between mechanistic insights and clinical translation remains a key challenge. Multi-targeted, combination, and precision-based therapeutic approaches, along with targeted drug delivery systems, may enhance treatment efficacy and overcome current limitations.
Conclusion:
Despite advances in understanding disease mechanisms, effective diseasemodifying therapies remain limited. The development of combination and personalized treatment strategies is essential for improving outcomes and preventing disease progression.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Cirrhosis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment: